Core Viewpoint - Illumina announced the acquisition of SomaLogic for $350 million in cash, with potential performance-based milestones and royalties totaling up to $75 million, aimed at strengthening its position in the growing proteomics market and enhancing its multi-omics strategy [1][2]. Group 1: Acquisition Details - The acquisition includes SomaLogic's aptamer-based affinity proteomics platform, which will enhance Illumina's presence in the high-growth proteomics sector [2]. - Illumina expects the business to achieve profitability based on non-GAAP operating income by 2027, with non-GAAP operating margins aligning with Illumina by 2028 [2]. - The transaction is subject to customary closing conditions, including regulatory approvals, with completion anticipated in the first half of 2026 [2]. Group 2: Strategic Implications - Illumina's CEO emphasized that the acquisition will enhance the value of the NovaSeq X product and unlock greater capabilities in the future [1]. - The collaboration between Illumina and SomaLogic has been ongoing for over three years, improving service capabilities and accelerating the technological roadmap for advanced biomarker detection and disease analysis [1]. - The integration of SomaLogic's technology is expected to apply the scalability of NGS (Next-Generation Sequencing) to proteomics, maintaining an open and empowering NGS platform [1]. Group 3: Company Background - SomaLogic employs approximately 250 staff globally, with operations in Boulder, Colorado, including CLIA and CAP certified laboratories [2]. - Prior to the acquisition, Illumina and SomaLogic had a joint development agreement established in December 2021 to implement SomaScan proteomics detection on Illumina's NGS platform [3].

Core Viewpoint - Zhejiang University has announced procurement intentions for 41 items of laboratory equipment, with a total budget of 102 million yuan, scheduled for procurement between April and July 2025 [1][2]. Procurement Overview - The procurement includes various laboratory instruments such as enzyme labelers, multifunctional enzyme labelers, chemiluminescence imaging systems, portable ultrasound imaging systems, digital slide scanners, and microscopes [2][3]. - The total budget for the procurement is 102 million yuan, with specific allocations for different equipment types [2][3]. Equipment Details - Enzyme Labeler: 1 unit, budget 200,000 yuan, used for detecting absorbance in microplate samples [3]. - Multifunctional Enzyme Labeler: 1 unit, budget 200,000 yuan, supports multiple detection modes [3]. - Chemiluminescence Imaging System: 1 unit, budget 200,000 yuan, used for Western Blot and gel imaging [3]. - Portable Ultrasound Imaging System: 1 unit, budget 200,000 yuan, supports various examination modes [3]. - Microscopes: Multiple units including inverted microscopes, automatic tissue dehydrators, and fluorescence microscopes, with a total budget of 343,000 yuan [3][4]. - Digital Slide Scanner: 1 unit, budget 370,000 yuan, for high-resolution imaging [4]. - High-Throughput ICP-MS: 1 unit, budget 198,000 yuan, for ppt-level metal ion detection [4][5]. - Atomic Layer Deposition System: 1 unit, budget 160,000 yuan, for precise material deposition [4][5]. - Turbine Engine: 2 units, budget 770,000 yuan, for educational and research purposes [4][7]. Additional Equipment - Various other equipment such as long-focus spherical interferometers, sample preprocessing systems, and high-performance liquid chromatography-mass spectrometry systems are also included in the procurement list, with budgets ranging from 110,000 to 300,000 yuan [5][6][12][13][19]. - The procurement aims to enhance research capabilities and educational practices at Zhejiang University, particularly in fields like aviation, chemistry, and materials science [7][8].

Core Viewpoint - The article highlights the upcoming "11th International Conference on Electron Microscopy (iCEM 2025)" scheduled for June 24-27, 2025, focusing on advancements in electron microscopy technology and its applications, particularly in the semiconductor industry [1][2]. Group 1: Conference Overview - The iCEM 2025 aims to provide a free learning platform for researchers in electron microscopy, leveraging internet technology to overcome geographical barriers [1]. - The conference will feature six thematic sessions, including innovative applications of electron microscopy in semiconductor manufacturing and discussions on domestic electron microscope technology [2]. Group 2: Industry Demand and Trends - There has been a rapid increase in demand for electron microscopy technology in China's industrial sector, particularly in the semiconductor industry, where it is essential for defect analysis, process optimization, and device development [2]. - The conference will introduce a special session on "Innovative Applications of Electron Microscopy in Semiconductor Manufacturing," emphasizing the integration of industry, academia, and research [2]. Group 3: Conference Schedule - The conference will span four days, with various sessions dedicated to different aspects of electron microscopy, including in-situ/environmental electron microscopy, advanced electron microscopy, and applications in life sciences [3][4][5][6][7].

Core Viewpoint - The revenue of multinational instrument companies in China has generally declined in 2024, with only Merck achieving growth, while many companies have experienced consecutive declines over the past two years due to multiple factors including US-China trade tensions, economic environment, and market competition [1][2]. Revenue Performance Summary - In 2024, Merck led the revenue rankings in China with $32.98 billion, marking a 5.8% increase after a 14.2% decline in 2023 [5][6]. - Danaher followed with $28.05 billion, down 10.8%, continuing a downward trend from $31.43 billion in 2023, which was a 13.0% decrease [6][8]. - Agilent ranked third with $12.20 billion, a decline of 11.6%, following a 7.9% drop in 2023 [7][8]. - Shimadzu and Mettler-Toledo ranked fourth and fifth with revenues of $6.30 billion and $6.22 billion, respectively, both experiencing declines [8]. - Overall, over 80% of the listed companies saw a year-on-year revenue decrease in 2024, with some companies facing declines for two consecutive years [8][14]. Market Share Analysis - The market share of many companies in China has also shown a downward trend, reflecting poor performance and indicating a relative decline in market vitality compared to global markets [9]. - In 2024, Agilent's market share in China was 18.74%, down from over 20% in previous years, indicating a significant drop [9]. Company-Specific Insights - Danaher reported that approximately 12% of its sales come from China, highlighting the potential adverse effects of the political, economic, and regulatory environment on its business [11]. - Waters experienced a notable 30% decline in sales in China, attributed to decreased demand across various customer categories due to economic conditions and trade tensions [12]. - Agilent's revenue decline was primarily driven by pressures in capital spending from clients, particularly in the pharmaceutical market [12]. - Mettler-Toledo emphasized the importance of the Chinese market, which accounted for 16% of its external sales, and noted the impact of geopolitical tensions and economic pressures on its performance [13]. Strategic Adjustments - In response to market changes, multinational companies are accelerating strategic adjustments, increasing investment in local R&D, and launching products tailored to local needs [15]. - Despite the challenges faced from 2022 to 2024, the long-term potential of the Chinese market remains significant, and companies are expected to adapt more flexibly and innovatively to maintain competitiveness [15].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 点击阅读原文报名 | 视 觉 ： 长 艳 柱 子 发 文 不 易 ， 请 帮 小 编 点 下 "❤️" | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号 立 场 | 转 载 ： 须 本 号 授 权 ， 请 后 台 回 复 " 合 作 " 联 系 主 编 | 来 源 ： 仪 器 信 息 网 | 责 编 ： 满 满 ...

Core Insights - The certification, accreditation, inspection, and testing industry in China has shown significant growth, with total revenue reaching 487.597 billion yuan, a year-on-year increase of 4.41% [2] - The industry possesses 10.6701 million sets of various instruments and equipment, reflecting a growth of 3.87% year-on-year, with the original asset value of these instruments amounting to 570.170 billion yuan, up by 8.01% [2][3] Group 1: Quality Certification Sector - The number of national certification agencies stands at 1,230, a decrease of 0.98% year-on-year, while the annual revenue for the sector totals 55.744 billion yuan, marking a growth of 10.82% [2] - The total number of valid certification certificates issued is 4,158,266, which is a year-on-year increase of 10.61% [2] - The number of certified organizations has reached 1,099,770, growing by 7.37% year-on-year, with certification personnel numbering 146,548, an increase of 3.58% [2] Group 2: Accreditation Sector - The China National Accreditation Service for Conformity Assessment (CNAS) has accredited a total of 20,251 organizations, including 283 certification bodies, 18,889 laboratories, 1,058 inspection bodies, and 21 auditing and verification bodies [3] Group 3: Inspection and Testing Sector - There are 53,057 inspection and testing institutions with qualification recognition, a year-on-year decrease of 1.44%, and the workforce in this sector is 1.55 million, down by 0.76% [3] - The total number of inspection and testing reports issued in the year is 551 million, which represents a decline of 8.66% year-on-year [3] - The average revenue per institution has increased by 5.94% year-on-year, while the average revenue per employee has grown by 5.20%, indicating improved industry structure and efficiency [3] Group 4: Industry Context - The certification, accreditation, inspection, and testing industry plays a crucial role in ensuring product quality, promoting industrial upgrades, and driving technological innovation in the context of global economic integration and trade liberalization [4] - The achievements in the certification and testing industry reflect its robust development, with expectations for continued quality improvement driven by favorable policies [5]

Core Viewpoint - The merger and acquisition is seen as a significant step for Nanhua Instruments to transition from traditional vehicle inspection to a dual track of "environmental protection + intelligent cleaning" [1][5] Group 1: Company Overview - Nanhua Instruments has disclosed its response to the Shenzhen Stock Exchange's inquiry regarding the restructuring, addressing the questions raised by the exchange [2] - Jiade Li is a national high-tech enterprise focused on innovation, providing comprehensive solutions for commercial cleaning equipment, including smart floor scrubbers and sweepers [3] - Jiade Li has achieved stable revenue growth, with projected revenues of 133 million yuan and 128 million yuan for 2023 and 2024, respectively, and corresponding net profits of approximately 21.99 million yuan and 17.66 million yuan [3] Group 2: Market Potential - The global B2B cleaning equipment market is projected to reach 28.3 billion yuan in 2023 and is expected to grow to 47.52 billion yuan by 2030, with a compound annual growth rate (CAGR) of 7.7% from 2024 to 2030 [5] Group 3: Performance Commitments - Jiade Li has provided performance commitments to Nanhua Instruments, promising a net profit of no less than 18 million yuan for 2025 and 20 million yuan for 2026, or a cumulative net profit of no less than 38 million yuan for 2025 and 2026 [6] - The stability of Jiade Li's team and its innovative capabilities will be maintained, while integrating its business and R&D capabilities into the overall development system of the listed company [6]

Core Insights - In the 25th week of 2025 (June 14-20), a total of 17 projects related to confocal microscopes were announced, with 6 projects awarded, totaling 6 units and a total bid amount of 16.251 million yuan [1][2] - There are 11 additional tender projects planned, with a total procurement quantity of 14 units and a disclosed budget exceeding 18.41 million yuan [2] Summary of Awarded Projects - The awarded projects include: - Nanjing Medical University: Super-resolution laser confocal microscope, brand: Nikon AX, date: June 20, 2025 - Hubei University: Laser scanning confocal microscope, brand: OLYMPUS, price: 1.959 million yuan, date: June 19, 2025 - Hebei Medical University: Laser confocal microscope, brand: ZEISS, price: 2.48 million yuan, date: June 18, 2025 - Shanghai Jiao Tong University: Multi-color photon quantitative confocal microscope, brand: Leica, price: 2.682 million yuan, date: June 17, 2025 - Ningbo University: Laser scanning confocal microscope, brand: Nikon AX, price: 2.46 million yuan, date: June 16, 2025 - Wenzhou Medical University: Laser confocal microscope, brand: ZEISS, price: 2.49 million yuan, date: June 16, 2025 [2] Summary of Tender Projects - The tender projects include: - Guangxi University: Laser scanning confocal microscope, budget: 1 million yuan, deadline: June 26, 2025 - Guangdong Agricultural Academy: Intelligent breeding platform, budget: 11.4 million yuan, deadline: July 2025 - Liaoning University of Traditional Chinese Medicine: Various confocal microscopes, budget: 16.802 million yuan, deadline: July 2025 - Capital Medical University: Laser confocal microscope, budget: 3.95 million yuan, deadline: July 9, 2025 - Beijing Normal University: Continuous spectrum laser confocal microscope, budget: 3.6 million yuan, deadline: July 2025 - Tongji University: Confocal microscope, budget: 1.77 million yuan, deadline: June 17, 2025 - Suzhou University: Ultra-high resolution confocal microscope system, deadline: July 7, 2025 - Fujian University of Technology: Laser confocal microscope, deadline: June 20, 2025 - Chongqing People's Hospital: Laser confocal microscope, budget: 3.4 million yuan, deadline: August 2025 - Quzhou People's Hospital: Laser confocal microscope, budget: 2.49 million yuan, deadline: July 1, 2025 - Xi'an Jiaotong University: High-resolution laser confocal microscope, budget: 3.2 million yuan, deadline: June 2025 [3][4]

Core Viewpoint - The article highlights the successful bids of Steel Research Nack's Plasma 3000 and Plasma 3500 ICP-OES instruments for key projects with customs authorities, showcasing the advancement of domestic high-end scientific instruments in breaking the monopoly of imported equipment [1][2][3]. Group 1: Project Achievements - Steel Research Nack's Plasma 3000 and Plasma 3500 ICP-OES have been awarded contracts by Guangzhou Customs, Tianjin Customs, and Huangpu Customs, indicating a strong recognition of the company's technological capabilities [2][3]. - The specific projects include the procurement of one unit each of Plasma 3000 for Guangzhou and Tianjin Customs, and one unit each of a high-frequency infrared sulfur analyzer and Plasma 3500 for Huangpu Customs [3]. Group 2: Technological Advancements - The Plasma 3000 ICP-OES is a key outcome of a national major scientific instrument development project, featuring advanced designs such as vertical plasma, dual observation interfaces, and a high-resolution optical system [4]. - The instrument employs cold cone technology to eliminate tail flame effects, a high-stability solid-state RF generator, and a large pixel area CCD chip for low-noise signal conversion, making it suitable for various fields including metallurgy, geology, and environmental analysis [4]. Group 3: Industry Position - The successful application of Steel Research Nack's instruments not only enhances customs detection efficiency and accuracy but also signifies a technological leap from "catching up" to "leading" in the domestic scientific instrument sector [7]. - Steel Research Nack is recognized as a leading enterprise in China's analytical instrument manufacturing, with a strong portfolio of products and services across multiple industries, including steel, aerospace, and environmental sectors [10].

Core Viewpoint - The European Union has decided to restrict Chinese companies from participating in medical device tenders exceeding 5 million euros, citing the International Procurement Instrument (IPI) as the basis for this decision. This move is perceived by China as unfair competition disguised as fair competition, and the Chinese government has vowed to protect the legitimate rights of its enterprises [1][3]. Group 1: Background and Context - The IPI was first proposed in 2012 and implemented in June 2022, allowing the EU to exclude companies from certain countries from large public tenders or impose punitive adjustments on their bids, potentially increasing them by 10%-20% [3]. - The restriction primarily affects high-end medical equipment contracts, such as proton therapy systems and advanced imaging devices, which are not common globally, including in China [6]. Group 2: Market Impact - The immediate industry reaction was one of concern, but this was quickly tempered as the actual impact of the regulation is considered limited. The majority of contracts above 40 million RMB are rare, and the EU market is largely a replacement market with limited new contracts [5][6]. - Chinese medical device companies are still in the early stages of international expansion and lack the long-term trust relationships with local public healthcare institutions that established companies like Siemens and Philips have [6]. Group 3: Historical Development of Chinese Medical Device Exports - The export journey of Chinese medical devices can be divided into three phases: 1. From the late 1990s to 2008, focusing on low-value consumables and simple diagnostic devices, with minimal technical content [7]. 2. From 2009 to 2015, where companies began to move beyond OEM and private label, increasing the export of mid-to-high-end devices [8]. 3. From 2016 to present, where there has been a significant output of low-value consumables alongside breakthroughs in high-end equipment, with a focus on localization in target markets to adapt to protectionist policies [8].